BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 22409211)

  • 1. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of respiratory effects with ivabradine in patients with asthma.
    Babu KS; Gadzik F; Holgate ST
    Br J Clin Pharmacol; 2008 Jul; 66(1):96-101. PubMed ID: 18341671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.
    Cass LM; Gunawardena KA; Macmahon MM; Bye A
    Respir Med; 2000 Feb; 94(2):166-73. PubMed ID: 10714424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment.
    Hancox RJ; Cowan JO; Flannery EM; Herbison GP; McLachlan CR; Taylor DR
    Respir Med; 2000 Aug; 94(8):767-71. PubMed ID: 10955752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
    Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
    Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
    Cappato R; Castelvecchio S; Ricci C; Bianco E; Vitali-Serdoz L; Gnecchi-Ruscone T; Pittalis M; De Ambroggi L; Baruscotti M; Gaeta M; Furlanello F; Di Francesco D; Lupo PP
    J Am Coll Cardiol; 2012 Oct; 60(15):1323-9. PubMed ID: 22981555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
    Nerla R; Di Franco A; Milo M; Pitocco D; Zaccardi F; Tarzia P; Sarullo FM; Villano A; Russo G; Stazi A; Ghirlanda G; Lanza GA; Crea F
    Heart; 2012 Dec; 98(24):1812-6. PubMed ID: 23086971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
    Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies.
    Koehler D; Pavia D; Dewberry H; Hodder R
    Respiration; 2004; 71(5):469-76. PubMed ID: 15467324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity.
    Papadopoulos NG; Philip G; Giezek H; Watkins M; Smugar SS; Polos PG
    J Asthma; 2009 May; 46(4):413-20. PubMed ID: 19484680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.